Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report). The associated price target remains the same with $45.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sam Slutsky’s rating is based on the promising potential of Abivax’s obefazimod in treating moderate-to-severely active ulcerative colitis. The upcoming Phase 3 ABTECT program results, expected in Q3 2025, are anticipated to be a significant catalyst for the stock, given the drug’s novel mechanism and oral delivery. The drug’s ability to address unmet needs in late-line refractory patients, coupled with its strong safety profile, further supports the positive outlook.
Additionally, the Phase 2 maintenance data have shown exceptional results, and if the Phase 3 induction data are positive, it would validate the earlier findings and enhance the prospects for the maintenance data. The potential for a New Drug Application submission in H2 2026, contingent on successful Phase 3 outcomes, adds to the investment appeal. Overall, the low current valuation of ABVX compared to historical IBD peers presents a compelling opportunity for investors.
According to TipRanks, Slutsky is an analyst with an average return of -6.2% and a 33.71% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Immunovant, Enliven Therapeutics, and Olema Pharmaceuticals.